Loading patent…
AssigneeWestvac Biopharma Co., Ltd.
InventorsXiawei WEI, Guangwen LU, Ping CHENG, Jingyun YANG, Li YANG, Jiong LI, Wei WANG, Zhiwei ZHAO, Yuquan WEI, Jinliang YANG, Zhenling WANG, Guobo SHEN
Estimating the term…
The present invention relates to a vaccine against respiratory syncytial virus infection and pertains to the field of medicine. To address the unmet need for effective prevention and treatment drugs against respiratory syncytial virus (RSV)-induced respiratory infection in the elderly, infants and immunocompromised persons, the present invention provides a vaccine against respiratory syncytial virus infection, and the vaccine uses adenovirus as the vector to express an engineered antigen gene specifically designed and optimized based on the fusion (F) protein sequence of RSV. The adenovirus vector vaccine can help the host to resist the respiratory syncytial virus infection, and has good prevention and treatment effect.
An adenovirus vector vaccine for preventing and/or treating respiratory syncytial virus infection, the adenovirus vector vaccine comprising a recombinant adenovirus vector comprising a respiratory syncytial virus expression gene, and a polynucleotide sequence of the respiratory syncytial virus expression gene is selected from at least one of SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32 and SEQ ID NO:34.
Dependencies are inferred from the claim text.